Op2Lysis September 2022 Corporate Orphan drug designation granted to OptPA for the treatment of non-traumatic spontaneous intracerebral hemorrhage by the European Commission Read More
Op2Lysis September 2022 Corporate Désignation de médicament orphelin pour OptPA pour le traitement de l’AVC hémorragique – Commission Européenne Read More
